Physician profile
Richard E Grant
NPI 1790942571
$6,272.33
in general payments reported to CMS, 2019-2025
25 companies · $641 in 2025
The $641 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $181 · 2021: $717 · 2022: $1,308 · 2023: $1,743 · 2024: $844 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.11 |
| Education | $146.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,688.45 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $467.45 | 2021-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $411.66 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.83 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $315.35 | 2019-2024 | Austedo, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $268.24 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $189.93 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $186.59 | 2021-2024 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $161.32 | 2019-2020 | |
| Lundbeck LLC | $153.58 | 2019-2024 | Rexulti |
| Eisai INC. | $152.50 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $149.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.78 | 2019-2023 | Trintellix |
| Almatica Pharma LLC | $119.03 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $91.88 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $87.19 | 2023 | |
| Axsome Therapeutics, INC. | $79.75 | 2022-2023 | Auvelity |
| Indivior INC. | $72.45 | 2022 | |
| Daiichi Sankyo INC. | $70.78 | 2019 | |
| Sunovion Pharmaceuticals INC. | $42.09 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.91 | 2022 | |
| Neuronetics, INC. | $30.75 | 2019 | |
| Masimo Corporation | $23.23 | 2023 | Emma and Isa |
| Pernix Therapeutics Holdings, INC. | $13.15 | 2019 | |
| Orexo US, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.